Gilead

Many, like CNBC’s Jim Cramer, would argue that the analyst community doesn’t get much of anything right. But it’s hard to argue that normally analysts are more than a few cents off when predicting a company’s quarterly EPS. So how did the analyst community get Tuesday’s Gilead (NASDAQ: GILD)...

U.S. stocks were slightly lower as positive labor market data clashed with fourth quarter GDP estimates that showed the economic expanded less than economists had expected. Major indices finished slightly lower as the Nasdaq index continues to see its losses fall sharper compared to the Dow and...

Don’t expect to get a direct answer from any of the big pharma firms, but in the world of big data, the answer, or something pretty close to answer, was found by doing some simple math. Last year, Forbes columnist Matthew Herper went back to the basics and simply divided each company’s spending...